JCB logo
PeproTech: Free Shipping at www.peprotech.com
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published 9 December 2002. doi:10.1083/jcb.200208112
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 640K)
Right arrow PPT slides of all figures
Right arrow Supplemental Material Index
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Uchiyama, K.
Right arrow Articles by Kondo, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Uchiyama, K.
Right arrow Articles by Kondo, H.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

© The Rockefeller University Press, 0021-9525/2002/12/855 $5.00
The Journal of Cell Biology, Volume 159, Number 5, 855-866


Article

VCIP135, a novel essential factor for p97/p47-mediated membrane fusion, is required for Golgi and ER assembly in vivo



Keiji Uchiyama1, Eija Jokitalo2, Fumi Kano3, Masayuki Murata3, Xiaodong Zhang4, Benito Canas5, Richard Newman6, Catherine Rabouille7, Darryl Pappin5, Paul Freemont4 and Hisao Kondo1,8

1 Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 2XY, United Kingdom
2 Institute of Biotechnology, University of Helsinki, Helsinki FIN-00014, Finland
3 National Institute for Physiological Sciences, Okazaki 444-8585, Japan
4 Centre for Structural Biology, Imperial College of Science, Technology and Medicine, London SW7 2AZ, United Kingdom
5 Clinical Pharmacology, Imperial College School of Medicine, London W12 0NN, United Kingdom
6 European Molecular Biology Laboratory-European Bioinformatics Institute, Cambridge CB10 1SD, United Kingdom
7 University Medical Centre Utrecht, Academic Ziekhuis Utrecht, 3584CX Utrecht, Netherlands
8 PREST and SORST, Japan Science and Technology Corporation, Saitama 332-0012, Japan

Address correspondence to Hisao Kondo, Cambridge Institute for Medical Research, Rm 5.36, University of Cambridge, Wellcome Trust/MRC Bldg., Hills Rd., Cambridge CB2 2XY, UK. Tel.: 44-1223-762632. Fax: 44-1223-762640. E-mail: hk228{at}cam.ac.uk

NSF and p97 are ATPases required for the heterotypic fusion of transport vesicles with their target membranes and the homotypic fusion of organelles. NSF uses ATP hydrolysis to dissociate NSF/SNAPs/SNAREs complexes, separating the v- and t-SNAREs, which are then primed for subsequent rounds of fusion. In contrast, p97 does not dissociate the p97/p47/SNARE complex even in the presence of ATP. Now we have identified a novel essential factor for p97/p47-mediated membrane fusion, named VCIP135 (valosin-containing protein [VCP][p97]/p47 complex-interacting protein, p135), and show that it binds to the p97/p47/syntaxin5 complex and dissociates it via p97 catalyzed ATP hydrolysis. In living cells, VCIP135 and p47 are shown to function in Golgi and ER assembly.

Key Words: membrane fusion; p97; VCIP135; Golgi; ER


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents